OncoC4 announced today that China's National Medical Product Administration (NMPA) has granted Breakthrough Therapy ...

Anti-CTLA-4 hopeful cleared for sprint to market after early data show rare tumour shrinkage in hard-to-treat patients.

Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma (RCC).

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Cambridge, Massachusetts Friday, October 24, 2025, 18:00 Hrs [IST] ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Replimune Group is conducting a pivotal Phase 3 clinical study ...

Professor Guan Xinyuan (left) and his research team developed the 'Cancer Immunology Data Engine', which is publicly ...

This overview provides a thorough review of current treatment approaches for first-line management of nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical ...

((HK:9926)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the ...

The global immunotherapy market is projected to experience robust growth at a rate of 13-14% annually through 2027. This growth is primarily driven by the rising incidence of cancer, alongside the ...